In collaboration with Faculty of Medicine, Chulalongkorn University, BioNet has advanced a clinical study on a next-generation pertussis vaccine, featuring a reduced-dose recombinant acellular pertussis formulation—from 5 μg to 2 μg while maintaining equivalent immune protection. This breakthrough not only enhances vaccine affordability but also expands accessibility for vulnerable groups, including pregnant women, adolescents, and adults with underlying health conditions. 

This achievement reflects our shared commitment to advancing public health through clinical research, vaccine innovation, and equitable access. We look forward to the positive impact this will bring to Thailand and global immunization efforts. 

Read the full article at: https://www.chula.ac.th/highlight/255127/